China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015, a molecular glue product, for clinical studies in hematological and solid tumors with RAS mutations. The approval follows positive preclinical data and a strategic licensing deal with U.S.-based Erasca, Inc.
Drug Profile
JYP0015, a novel pan-RAS small molecule inhibitor, has shown high anti-tumor activity in preclinical models of RAS mutations. The drug exhibits favorable pharmacokinetic (DMPK) properties, oral bioavailability, and a strong safety profile, positioning it as a promising candidate for RAS-driven cancers.
Licensing Partnership
In May 2024, Joyo Pharma entered a $345 million licensing agreement with Erasca (NASDAQ: ERAS), granting the California firm exclusive global rights (excluding mainland China, Hong Kong, and Macau) to develop and commercialize JYP0015. Erasca has initiated the AURORAS-1 study to evaluate the drug’s efficacy and safety in RAS mutant solid tumors.-Fineline Info & Tech
